Clinical Efficacy of Therapy with Recombinant Human Interferon α1b in Hand, Foot, and Mouth Disease with Enterovirus 71 Infection

Abstract

UNLABELLED A rapid expansion of HFMD with enterovirus 71 infection outbreaks has occurred and caused deaths in recent years in China, but no vaccine or antiviral drug is currently available for EV71 infection. This study aims to provide treatment programs for HFMD patients. We conducted a randomized, double-blind, controlled trial and evaluated clinical efficacy of therapy with rHuIFN-α1b in HFMD patients with EV71 infection. There were statistical differences in outcomes including the fever clearance time, healing time of typical skin or oral mucosa lesions, and EV71 viral load of the HFMD patients among ultrasonic aerosol inhalation group, intramuscular injection group and control group. rHuIFN-α1b therapy reduced the fever clearance time, healing time of typical skin or oral mucosa lesions, and EV71 viral load in children with HFMD. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR-TRC-14005153.

DOI: 10.1371/journal.pone.0148907

Extracted Key Phrases

Cite this paper

@inproceedings{Huang2016ClinicalEO, title={Clinical Efficacy of Therapy with Recombinant Human Interferon α1b in Hand, Foot, and Mouth Disease with Enterovirus 71 Infection}, author={Xueyong Huang and Xi Zhang and Fang Wang and Haiyan Wei and Hong Ma and Meili Sui and Jie Lu and Huaili Wang and John Stephen Dumler and Guangyao Sheng and Bian-Li Xu and Marc Steven Horwitz}, booktitle={PloS one}, year={2016} }